Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers.

Eighteen healthy volunteers received three different formulations of Ginkgo biloba: capsules (A) and drops (B) (delivered by Agon Pharma), and tablets (C) (Tebonin-Dr. W. Schwabe) in equal an quantity, orally as a single dose, at an interval of at least five days.

[Acute intermittent porphyria--diagnostic difficulties and treatment].

A patient is described in whom acute intermittent porphyria was diagnosed after 6 months of treatment and five stays in hospital during which the cause of her manifestations was not established. Treatment of the patient and principles of treatment of acute attack of intermittent porphyria are described.